Graph-Radiomic Learning (GrRAiL) Descriptor to Characterize Imaging Heterogeneity in Confounding Tumor Pathologies
This work addresses the problem of reliable tumor diagnosis for clinicians by providing an incremental method to enhance imaging-based classification in oncology.
The paper tackled the challenge of distinguishing confounding pathologies from malignant tumors on MRI by developing the Graph-Radiomic Learning (GrRAiL) descriptor, which improved test accuracies by over 10% in three clinical use cases, such as achieving 78% accuracy for glioblastoma recurrence detection.
A significant challenge in solid tumors is reliably distinguishing confounding pathologies from malignant neoplasms on routine imaging. While radiomics methods seek surrogate markers of lesion heterogeneity on CT/MRI, many aggregate features across the region of interest (ROI) and miss complex spatial relationships among varying intensity compositions. We present a new Graph-Radiomic Learning (GrRAiL) descriptor for characterizing intralesional heterogeneity (ILH) on clinical MRI scans. GrRAiL (1) identifies clusters of sub-regions using per-voxel radiomic measurements, then (2) computes graph-theoretic metrics to quantify spatial associations among clusters. The resulting weighted graphs encode higher-order spatial relationships within the ROI, aiming to reliably capture ILH and disambiguate confounding pathologies from malignancy. To assess efficacy and clinical feasibility, GrRAiL was evaluated in n=947 subjects spanning three use cases: differentiating tumor recurrence from radiation effects in glioblastoma (GBM; n=106) and brain metastasis (n=233), and stratifying pancreatic intraductal papillary mucinous neoplasms (IPMNs) into no+low vs high risk (n=608). In a multi-institutional setting, GrRAiL consistently outperformed state-of-the-art baselines - Graph Neural Networks (GNNs), textural radiomics, and intensity-graph analysis. In GBM, cross-validation (CV) and test accuracies for recurrence vs pseudo-progression were 89% and 78% with >10% test-accuracy gains over comparators. In brain metastasis, CV and test accuracies for recurrence vs radiation necrosis were 84% and 74% (>13% improvement). For IPMN risk stratification, CV and test accuracies were 84% and 75%, showing >10% improvement.